Pharmya

  • Home
  • About us
  • Services
    • Pharmacovigilance Systems
    • Operational Pharmacovigilance Activities
    • EU QPPV & Local QPPV services
    • Pharmacovigilance Audits and Training
  • News
  • Careers
  • Contact us
  • English
  • Français
  • Español
You are here: Pharmya > All news > MedDRA : whatsnew ?
MedDRA-whatsnew_25_1_Sep2022-1Télécharger
Marie Berger 26 September 2022 All news
  • ← Update on the surveillance of vaccines and treatments against the Monkeypox virus
  • Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022 →

Pharmya – Pharmacovigilance

PHARMYA is a French based company, dedicated to providing Pharmacovigilance services. Its mission is to support the pharmaceutical industry, biotechnology companies, research centers and their service providers in their efforts to comply with international Pharmacovigilance regulations.

Contact

  • PHARMYA
  • 315 Av. Saint Sauveur du Pin
  • 34980 Saint Clément de Rivière (Montpellier), France
  • Phone: +33 411 93 21 10
  • Email: info@pharmya.com
  • Website: www.pharmya.com

News

  • Austria: FAQ Pharmacovigilance – 22-Nov-2022
  • Benfluorex: assessment of the follow-up of cases of pulmonary arterial hypertension
  • EU : List of centrally authorised products requiring a notification of a change for update of annexes
Copyright © 2018 - Pharmya - Legal terms - Quality Policy